Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating and a $15 price target. The firm launched coverage of the specialty pharmaceuticals industry with a neutral view, noting that investor sentiment is starting to improve as companies place more emphasis on innovat ...